Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 589 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07623265Recruiting
Understanding Immunotherapy Response in Liver Cancer
This study collects tumor samples and medical information from patients with liver cancer to understand why some patients respond better to immunotherapy (immune-boosting drugs) than others. The goal is to improve treatment selection and outcomes for future patients.
AntwerpAges 18 years+ - NCT07628751Recruiting
Standard care versus radiation therapy for early-stage liver cancer
This study compares two treatment approaches for early-stage liver cancer: standard treatments (like ablation or chemotherapy injected into blood vessels) versus a newer radiation therapy called SABR. The goal is to see which approach works better and is safer for patients with a single small tumor.
WaratahAges 18 years+ - NCT07639138RecruitingPhase 2
Lenalidomide with targeted therapy and immunotherapy for advanced liver cancer
This trial tests whether adding lenalidomide (a drug that boosts the immune system) to your current targeted therapy and immunotherapy can help advanced liver cancer that has progressed after previous treatments. You would be eligible if your cancer has already been treated with at least two prior drug combinations and initially responded before growing back.
Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, ChinaAges 18–75 - NCT07658833Recruiting
Combined therapy for large liver cancer with vein clot
This trial combines a targeted drug and immunotherapy with procedures that deliver cancer-killing beads or chemotherapy directly to your liver tumor. It is designed for people with large, inoperable liver cancer that has spread into the main vein leading to the heart.
Guangzhou, None SelectedAges 18–75 - NCT07617038Enrolling by invitation
MRI Scan to Predict Liver Cancer Treatment Response
This trial uses a special type of MRI scan to see if doctors can predict how well a liver cancer treatment (called TACE) will work for you. The scan may help doctors understand your treatment response better.
Montreal, QuebecAges 18–70 - NCT07290764Enrolling by invitation
Surgery vs observation for liver cancer that responded to drug therapy
This trial looks at whether people with an initially untreatable liver cancer that has shrunk or disappeared after drug therapy should have surgery or just continue monitoring. It aims to see which approach helps people live longer.
Fuzhou, FujianAges 18–75 - NCT07052448Enrolling by invitation
Radiation after triple therapy for liver cancer
This trial tests whether adding radiation therapy after a combination of three treatments (like immunotherapy and targeted therapy) can help people with liver cancer that cannot be surgically removed. It may be a good option if your tumor responded to the triple therapy but you still cannot have surgery.
Fuzhou, FujianAges 18–75 - NCT06882876Enrolling by invitationPhase 1
Study of JS014, Toripalimab and TACE for Untreated Liver Cancer
This trial combines an investigational drug (JS014) with a standard immunotherapy (Toripalimab) and a procedure called TACE (tiny beads placed into the liver's blood vessels to block tumor feeding) for people with advanced liver cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink tumors or slow their growth.
Changsha, HunanAges 18–75 - NCT06773260Enrolling by invitation
Using liver stiffness to predict varices in advanced liver cancer
This trial uses a simple ultrasound test (measuring liver and spleen stiffness) to predict if a patient with cirrhosis and advanced liver cancer has enlarged veins in the esophagus. The goal is to avoid unnecessary invasive procedures like endoscopy.
Bari, ItalyAges 18–80 - NCT06647264Enrolling by invitation
Study on computer-aided risk prediction for liver and gallbladder surgery
This study uses a computer program to help doctors predict risks and outcomes for patients having laparoscopic liver or gallbladder surgery. It may help improve how doctors plan and manage your care before, during, and after surgery.
Guangzhou, GuangdongAges 18–80 - NCT06061328Enrolling by invitation
Project OASIS: Finding better ways to improve care for cirrhosis
This trial tests different approaches to help doctors and hospitals improve care for veterans with cirrhosis. If you have cirrhosis and are not post-transplant or currently being treated for liver cancer, you might be able to join and help find the best strategies.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05441475Enrolling by invitationPhase 2
Trial for advanced liver cancer using ABSK-011 plus atezolizumab
This Phase 2 study tests ABSK-011 combined with either atezolizumab or the usual care in people with advanced or unresectable liver cancer. It aims to see if the treatment helps shrink tumors and control the cancer when standard options aren’t working or can’t be used.
Hubei, Shanghai MunicipalityAges 18 years+ - NCT04539717Enrolling by invitation
Fast MRI test for liver cancer screening
This study tests a quicker MRI screening approach for people with cirrhosis to look for liver cancer early. It may help make liver cancer checkups faster and easier while still finding cancers when they are small.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 589 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.